Primary Research

 
Stock Quotes for Primary Research top ^
  • Industry: Utilities - Independent Power Producers
  • Sector: Utilities
  • Stock Style: Small Value
Sign-up for 8pen investment picks
  • Industry: Utilities - Independent Power Producers
  • Sector: Utilities
  • Stock Style: Small Value
  • Stock Type: Slow Growth
Sign-up for pri investment picks

 
Fund Quotes for Primary Research top ^
  • Holdings: Intel Corp , Royal Dutch Shell PLC ADR Class A , Encana Corp , Schlumberger NV , Pfizer Inc ,
  • Category: Large Value
  • Morningstar Rating: 2 Stars
Sign-up for ptfdx investment picks
  • Holdings: Roche Holding AG , Samsung Electronics Co Ltd , Sanofi , Bayer AG , GlaxoSmithKline PLC ,
  • Category: Foreign Large Value
  • Morningstar Rating: 4 Stars
Sign-up for tfeqx investment picks
  • Holdings: Roche Holding AG , Samsung Electronics Co Ltd , Sanofi , Bayer AG , GlaxoSmithKline PLC ,
  • Category: Foreign Large Value
  • Morningstar Rating: 4 Stars
Sign-up for us8802105051 investment picks

 
News Articles for Primary Research top ^
OAK BROOK, IL , April 22, 2014 /PRNewswire/ - Primary Energy Recycling Corporation (TSX: PRI) (Primary Energy or the Company) today announced that its Board of Directors has declared a quarterly dividend on the common shares of the Company (the "Shares") in the amount of US$0.07 per Share.
Sign-up for Primary Energy Recycling Announces Quarterly Dividend investment picks
OAK BROOK, IL , April 22, 2014 /PRNewswire/ - Primary Energy Recycling Corporation (TSX: PRI) , a clean energy company that generates revenue from capturing and recycling recoverable heat and by-product fuels from industrial processes, today announced its financial and operational results for the first quarter ended March 31, 2014 .
Sign-up for Primary Energy Reports First Quarter 2014 Results investment picks
Achieved Primary Endpoint of Complete Response (CR) in the Delayed Period (24 to 120 Hours) Following Initiation of Chemotherapy Achieved Key Secondary Endpoints of CR in the Acute and Overall Periods Achieved All Secondary Endpoints, Including No Significant Nausea Adverse Event Profile Consistent with Earlier Clinical Trials New Drug Application (NDA) Submission to U.S. FDA On Track for Mid-2014 WALTHAM, Mass., May 12, 2014 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) , an oncology-focused biopharmaceutical company, today announced positive top-line results from the third and final Phase 3 trial of rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). The rolapitant arm in this trial, which enrolled patients receiving cisplatin-based, highly emetogenic chemotherapy (HEC), successfully achieved statistical significance over the standard
Sign-up for TESARO Announces Successful Achievement of Primary and All Secondary Endpoints in Third and Final Phase 3 Trial of Rolapitant investment picks
Latest Data Sweep from Large Subgroup of Patients Shows a Strong 50% Improvement in Overall Survival for ThermoDox® Pisa University's Professor Riccardo Lencioni Highlights HEAT Study Post-Hoc Analysis, Rationale for the Phase III OPTIMA Study LAWRENCEVILLE, N.J. , April 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that updated results from the 701 patient HEAT Study post-hoc analysis, as well as a review of the final study design of the Phase III OPTIMA Study, which both explore ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer, were presented at the 5 th European Conference on Interventional Oncology (ECIO) on April 24, 2014 in Berlin , Germany.
Sign-up for Celsion Corporation Announces Updated Overall Survival Results from the HEAT Study of ThermoDox® in Primary Liver Cancer Presented at ECIO 2014 investment picks
2014/4/28
First available data demonstrated a 56% reduction of dengue disease cases in a study of more than 10,000 volunteers from Asia  Initial safety data are consistent with the good safety profile observed in previous studies   LYON, France, April 28, 2014 (GLOBE NEWSWIRE) -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), today announced that the first of two pivotal Phase III efficacy studies with its dengue vaccine candidate has achieved its primary clinical endpoint.
Sign-up for The World's First, Large-Scale Dengue Vaccine Efficacy Study Successfully Achieved Its Primary Clinical Endpoint investment picks
EAST AURORA, N.Y., May 21, 2014 (GLOBE NEWSWIRE) -- Astronics Corporation (Nasdaq:ATRO) , a leading provider of advanced technologies for the global aerospace and defense industries, announced today that it has been selected to provide the primary power distribution system for the Daher-Socata TBM 900 aircraft.
Sign-up for Astronics Selected to Provide Primary Electronic Power System for Daher-Socata 2014 TBM 900 investment picks
NEW YORK , April 28, 2014 /PRNewswire/ -- Scientific Games Corporation (Nasdaq: SGMS) (the "Company") today announced it has signed a new contract to provide instant games and related services for Washington's Lottery , a customer since 1990.
Sign-up for Scientific Games Signs Primary Instant Games Contract with Washington State Lottery investment picks
2014/5/1
MM-398 in combination with 5-fluorouracil and leucovorin demonstrates statistically significant advantage compared to control arm Plan to submit New Drug Application in 2014 Conference Call Scheduled for 8:30 a.m. ET Today CAMBRIDGE, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival of 6.1 months, a 1.9 month improvement over the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone.
Sign-up for Merrimack Pharmaceuticals Announces MM-398 Achieves Primary Endpoint of Overall Survival in Phase 3 Trial in Post-Gemcitabine Metastatic Pancreatic Cancer investment picks
http://media.marketwire.com/attachments/201301/122871_brocadelogo.gif http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1112194&ProfileId=051205&sourceType=1 LAS VEGAS, NV --
Sign-up for Brocade Redefines SAN Management and Operation for EMC Entry-Level Primary Storage and Data Protection Solutions for EMC Business Partner Program Participants investment picks
- On Track for Study Participation in Major HCC Markets Worldwide - LAWRENCEVILLE, N.J. , May 21, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced it has received regulatory clearance to initiate its Phase III OPTIMA Study at clinical trial sites in Taiwan , Hong Kong , South Korea and Canada.
Sign-up for Celsion Advances Global Regulatory Efforts in Support of Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Primary Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Primary Energy Recycling  |  Next: Principal Financial